Fatty liver disease has quietly become one of the most common liver conditions in the UK, and interest in whether weight-loss peptides could treat it has grown alongside the wider GLP-1 boom. That interest is no longer purely speculative: in July 2026 the UK's medicines regulator gave a peptide-based treatment its first licence for this specific condition. This guide sets out what fatty liver disease is, what the trial evidence for GLP-1 peptides actually shows, exactly what is licensed in the UK right now, and why peptides marketed online for "liver support" are a different matter entirely.
What fatty liver disease is
Metabolic dysfunction-associated steatotic liver disease (MASLD), still often called fatty liver disease and previously known as NAFLD, happens when fat builds up in the liver in people who drink little or no alcohol. It is closely linked to excess weight, type 2 diabetes and insulin resistance, and the British Liver Trust estimates it affects around one in five adults in the UK, making it the most common chronic liver condition in the country. Most people with MASLD have no symptoms at all, and many are only diagnosed after an unrelated blood test or scan picks up raised liver enzymes or fat in the liver.
In a smaller proportion of people, MASLD progresses to a more serious form called metabolic dysfunction-associated steatohepatitis (MASH), where the liver becomes inflamed and starts to sustain damage rather than simply storing excess fat. Left unmanaged, MASH can lead to scarring of the liver tissue, known as fibrosis, and over years this can advance to cirrhosis. The distinction matters clinically: simple fatty liver is generally reversible with lifestyle change, while MASH with significant fibrosis is what the newer licensed treatments, and the research described below, are specifically aimed at.
Why GLP-1 peptides are being studied for liver health
GLP-1 receptor agonists such as semaglutide and tirzepatide were developed for type 2 diabetes and later weight management, but researchers noticed liver-related improvements in people taking them well before any liver-specific trials began. The proposed mechanism is not mysterious: these medicines reduce appetite and support meaningful weight loss, and weight loss itself is one of the most effective ways to reduce liver fat. GLP-1 receptor agonists also appear to have direct effects on insulin sensitivity and inflammation that may help independently of weight change, though the relative contribution of each pathway is still being studied.
The clinical trial data now backs this up at a scale regulators can act on. The phase 3 ESSENCE trial tested semaglutide 2.4mg in adults with biopsy-confirmed MASH and moderate-to-advanced fibrosis. At a planned 72-week interim analysis, 62.9% of people on semaglutide achieved resolution of MASH compared with 34.2% on placebo, and 36.8% achieved an improvement in fibrosis without their MASH getting worse, compared with 22.4% on placebo. Both results were statistically significant and were published in the New England Journal of Medicine. Tirzepatide has shown a similar signal in an earlier, smaller phase 2b trial called SYNERGY-NASH: MASH resolution without worsening fibrosis was reached by 44%, 56% and 62% of participants across the three tirzepatide dose groups, compared with 10% on placebo, alongside improvements in liver fat, liver blood tests and fibrosis markers.
What's actually licensed for MASH in the UK right now
This is the part that changes fastest, so it is worth being precise. In July 2026, the MHRA granted semaglutide (branded as Wegovy for this use) a conditional marketing authorisation to treat MASH in adults with moderate-to-advanced liver fibrosis, based on the ESSENCE interim results. It is a genuine, regulator-approved licence, not an off-label extrapolation from the weight-management data, though "conditional" means the MHRA will review further evidence from the ongoing trial before converting it to a full licence. Resmetirom, a different, non-peptide medicine, was authorised around the same time for the same indication, so semaglutide is not the only newly licensed option for MASH, though it is the one directly relevant to this article's focus on peptides.
Two practical points matter more than the headline. First, this licence is specifically for MASH with fibrosis, confirmed through liver testing, not simply for having fatty liver on a scan; it is not a general "fatty liver treatment" available to anyone who asks for it. Second, having a UK licence is not the same as having NHS funding. NICE is currently appraising both semaglutide and resmetirom for MASH, and until that appraisal concludes, the medicine is not routinely available on the NHS for this specific indication, even though it has been prescribable on the NHS for weight management and cardiovascular risk reduction for some time. Tirzepatide, by contrast, does not currently hold any UK licence for liver disease at all; its SYNERGY-NASH results are encouraging phase 2b data, not a basis for prescribing it for this purpose today.
Unlicensed "liver support" peptides and the real risks
Alongside the licensed medicines above, a separate market sells peptides online with claims about liver health, detoxification or fat metabolism that have nothing to do with MHRA-assessed evidence. Compounds like BPC-157 are commonly marketed this way, often labelled "research use only" precisely so the seller avoids claiming the product is safe or effective for human use. That labelling is a legal disclaimer, not a safety standard, and it should be read as a warning rather than reassurance.
The risks with these products are practical as well as legal. Nobody outside the seller has verified what is actually in the vial, at what strength, or whether it was manufactured and stored to any meaningful standard; independent testing of similar grey-market products has repeatedly found contents that do not match the label. There is no prescriber assessing whether a peptide is safe alongside your other medicines or existing health conditions, including liver disease itself, where an unverified product could plausibly do harm rather than good. If something goes wrong, there is no clinical support behind the purchase and no reliable record of exactly what was taken. For a fuller look at how these products are regulated (or not), see our guide to whether peptides are legal in the UK, and on the practical hazards of preparing them at home, our guide to reconstituting peptides at home.
Evidence-based management today
For most people with MASLD, and even many with early MASH, NICE guidance still places lifestyle change at the centre of management: gradual, sustained weight loss through diet and increased physical activity, alongside management of associated conditions like type 2 diabetes, high blood pressure and high cholesterol. NICE specifically notes evidence that exercise reduces liver fat content independently of weight change, and does not recommend supplements such as omega-3 fatty acids for MASLD, since the evidence for them is not strong enough to support routine use.
Diagnosis and monitoring in the UK typically starts with liver blood tests and an ultrasound scan, often prompted by another investigation rather than symptoms, followed by a non-invasive fibrosis assessment such as a Fibroscan or a blood-based fibrosis score if fatty liver is confirmed. This staging step matters because it is what determines whether someone might be a candidate for licensed pharmacological treatment such as semaglutide, once NHS funding decisions catch up with the MHRA licence, or whether lifestyle management alone remains the appropriate first step. If you have been told you have fatty liver disease, or you are concerned about your risk because of your weight, blood sugar or family history, the safest route is a conversation with your GP or a registered clinician who can arrange appropriate testing rather than a peptide bought online on the strength of a forum recommendation.